Completion of non-exclusive discounts pursuant to § 130a para. 8 SGB V for pharmaceuticals with the active substance Entecavir (ATC: J05AF10) as part of a so-called open-house model.
Completion of non-exclusive discounts pursuant to § 130a para. 8 SGB W for pharmaceuticals with the active substance Fulvestrant (ATC: L02BA03) as part of a so-called open-house model.
Completion of non-exclusive discounts pursuant to § 130a para. 8 SGB W for pharmaceuticals with the active substance acitretin (ATC: D05BB02) as part of a so-called open-house model.